Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics tags : Clinical-trials-phase-ii save search
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.7827 -2.16% -2.21% 200K
|
Manufacturing
|
| O: -16.22%
H: 0.99%
C: -7.89%
first melanoma update therapeutics advanced
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
ALGS | $0.735 -7.33% -7.9% 140K
|
Health Technology
|
| O: 2.25%
H: 4.0%
C: 1.0%
alg-0550 first therapeutics study
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: -0.23%
H: 0.54%
C: -1.13%
jnj-2113 psoriasis study
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Published: 2024-01-30 (Crawled : 13:00) - biospace.com/
CMMB | $0.691 -1.29% -1.3% 15K
|
Manufacturing
|
| O: 5.56%
H: 5.26%
C: 1.75%
ccl24 antibody publication cm-101 therapeutics potential
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Published: 2024-01-04 (Crawled : 13:30) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.9%
H: 1.18%
C: -1.18%
update therapeutics platform
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-12-13 (Crawled : 13:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: 0.1%
H: 3.85%
C: 3.72%
jnj-2113 active payment milestone study
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
Published: 2023-12-11 (Crawled : 15:30) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -1.87%
H: 0.0%
C: -4.76%
al001 fda drug lithium trial
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -6.85%
al001 drug candidate lithium application trial
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
Published: 2023-11-09 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.81%
H: 0.43%
C: -2.1%
ttx-030 cancer pancreatic trial therapeutics phase 2
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
Published: 2023-10-31 (Crawled : 23:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 11.35%
H: 9.32%
C: -4.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.0%
H: 3.76%
C: 3.75%
cyb003 rapid positive depression meeting
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M
|
Health Technology
|
| O: 1.67%
H: 9.84%
C: 8.2%
rg6501 opregen macular rapid results show
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin
Published: 2023-10-03 (Crawled : 13:30) - biospace.com/
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: -2.08%
H: 3.72%
C: 3.19%
positive meeting therapeutics study
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Published: 2023-09-19 (Crawled : 14:00) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.18%
H: 5.8%
C: 2.92%
covid-19 study
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
Published: 2023-09-18 (Crawled : 22:00) - biospace.com/
VTVT | $24.74 -0.21% 2K
|
Health Technology
|
| O: 1.15%
H: 6.62%
C: 3.51%
hospital treatment pharmaceuticals azeliragon glioblastoma study
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
Published: 2023-09-12 (Crawled : 13:30) - biospace.com/
VTGN | $4.77 1.49% 1.47% 150K
|
Health Technology
|
| O: 0.75%
H: 4.12%
C: -3.28%
ph80 management positive results study
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
Published: 2023-08-30 (Crawled : 15:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.07%
H: 3.21%
C: 0.0%
al001 drug lithium application trial
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Published: 2023-08-28 (Crawled : 20:00) - biospace.com/
VTVT | $24.74 -0.21% 2K
|
Health Technology
|
| O: 1.01%
H: 4.9%
C: 0.92%
treatment pharmaceuticals azeliragon trial
Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response
Published: 2023-08-22 (Crawled : 13:20) - biospace.com/
PSNL | $1.31 8.26% 7.63% 280K
|
Health Technology
|
| O: 1.69%
H: 0.56%
C: -1.67%
therapeutics response molecular
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.